Squamous cell carcinoma of head and neck
Not yet recruitingPhase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Disease:Squamous cell carcinoma of head and neck
- Substances:Ficerafusp alfaPembrolizumab
Germany- Participants:18–64 years · 65+ years
- Substances:Ficerafusp alfa
- Sponsor:Bicara Therapeutics Inc.










